Zacks Investment Research on MSN
Sarepta plans FDA filings seeking full approval for two DMD therapies
Sarepta Therapeutics SRPT announced plans to submit supplementary new drug applications (sNDAs) to the FDA for its two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results